Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cetrorelix Pamoate · 1 trial · 1 indication
International Prostate Symptom Score (IPSS) Patient Questionnaire assessing 7 items (incomplete voiding, frequency, intermittency, urgency, weak stream, hesitancy, nocturia) on a scale from 0 (best) to 5 (worst); total range: 0 - 35 points; absolute change from baseline to Week 26
| Arm | Type | Description |
|---|---|---|
| Cetrorelix 78 mg | EXPERIMENTAL | Drug: Cetrorelix 52 mg week 0, and 26 mg week 2, intra muscular-2 doses in 2 weeks and follow up to week 26. |
| Name | Type | Description |
|---|---|---|
| Cetrorelix Pamoate | DRUG | Cetrorelix Pamoate IM, 52 mg week 0, 26 mg week 2, |
Inclusion Criteria: * Benign Prostatic Hyperplasia, based on medical history * Voiding symptoms * Uroflow (max) 5-15mL/sec Exclusion Criteria: * Urgent need for prostate surgery * History of allergic reaction to peptide * Major organ dysfunction * Prior surgical treatment of the prostate or bladd...
Cetrorelix Pamoate is an investigational small molecule developed by COSCIENS Biopharma Inc. (ticker CSCI) for symptomatic benign prostatic hypertrophy, also called benign prostatic hyperplasia or BPH. It is a gonadotropin-releasing hormone receptor antagonist being studied in a Phase 3 clinical program in urology.
Cetrorelix Pamoate is being developed to treat symptomatic benign prostatic hypertrophy (BPH) in men. The Phase 3 study enrolled men aged 50 years and older with symptomatic BPH in the United States and Canada. It is investigational and has not been approved for this or any other use.
Cetrorelix Pamoate targets GNRHR, the gonadotropin-releasing hormone receptor, and acts as an antagonist at that receptor. By blocking this receptor, the drug is designed to suppress gonadotropin signaling. This mechanism underlies its development for symptomatic benign prostatic hypertrophy.
Cetrorelix Pamoate is being developed by COSCIENS Biopharma Inc., which trades under the ticker CSCI. The company is the sponsor of the Phase 3 clinical program evaluating the drug in symptomatic benign prostatic hypertrophy.
Cetrorelix Pamoate is in Phase 3 development for symptomatic benign prostatic hypertrophy. It is investigational and has not been approved by the FDA. One Phase 3 trial has been completed, and no trials are currently listed as active.
Cetrorelix Pamoate has been studied in one Phase 3 trial, NCT00670306, titled Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH). The completed study enrolled 528 men aged 50 years and older in the United States and Canada and was uncontrolled.